Adj. EBITA SEK 57m, 6% below ABGSCe SEK 61m* Organic growth softer than expected* Consensus adj. EBITA revisions likely down ...

Net sales SEK 616m, -1% vs ABGSCe and Factset cons.* EBITA SEK 83m, -6% vs ABGSCe, -4% vs cons* Report moves cons. '26e EBITA ...

Xvivo Perfusion (Q3 Initial take): Strong sales growth, boosted by Thoracic - Redeye ...

Q3 sales 6% above our ests. at SEK 260m, for 20% org. growth* EBITA SEK 27m vs. ABGSCe 20m* Trading at 9x-7x '27e-'28e ...

Sequential sales decline, but order activity has improved* We lift '26e/'27e/'28e EBIT by 9%/7%/6%* 14-11x '26e-'27e EV/EBIT ...

Q3e sales +6%, with 5% organic growth* Raised EBITA driven by new contracts* Share trading at 15x '26e EV/EBITA, goes to 9x ...

Q3e: sequential step-up in organic growth and margin* M&A the main driver behind our EBITA upgrades* Two new acquisitions end ...

ATOSS will release preliminary Q3 figures on Friday. We expect another strong quarter, which should make the margin guidance ...

We lower total ‘27e-‘28e sales by 4%, see break-even in FY'27e* Recycling +66% y-o-y, record trial activity and growing ...

Demand stabilising, but reduction in FTEs a headwind* We cut adj. EBITA by 6% for '26e and 10% for '27e* Trading at ...

EBIT -20% vs. ABGSCe on timing and tech costs* We lower ‘26e-‘28e sales by 3% and EBIT adj. by 4%/6%/5%* EU vote outcome ...

Q3e EBITDA of NOK 10m, top line flat q-o-q* Meijer kicks off the US opportunity* Fair value range of NOK 8-18 per share ...